Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kontafarma China Holdings Ltd ( (HK:1312) ) has shared an announcement.
Kontafarma China Holdings Ltd reported its unaudited interim results for the six months ending June 30, 2025, showing a significant financial downturn compared to the previous year. The company experienced a substantial loss of HK$321.4 million, primarily due to increased impairment losses and other financial setbacks, impacting its profitability and market position.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd is a company incorporated in the Cayman Islands, operating in the industry of pharmaceuticals and health-related products. The company focuses on the production and distribution of various pharmaceutical products and health services, catering to a diverse market in China.
Average Trading Volume: 1,193,052
Technical Sentiment Signal: Sell
Current Market Cap: HK$167.4M
See more data about 1312 stock on TipRanks’ Stock Analysis page.